In this study, we found that imatinib-induced RACK1 expression reactivated the ERK and Akt signaling pathways in c-KIT-mutant GIST cells, thereby attenuating the antitumor effects of imatinib. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.